A phase II multi-institutional study assessing simultaneous in-field boost helical tomotherapy for 1-3 brain metastases

George Rodrigues, Slav Yartsev, Keng Yeow Tay, Gregory R Pond, Frank Lagerwaard, Glenn Bauman, George Rodrigues, Slav Yartsev, Keng Yeow Tay, Gregory R Pond, Frank Lagerwaard, Glenn Bauman

Abstract

Background: Our research group has previously published a dosimetric planning study that demonstrated that a 60 Gy/10 fractions intralesional boost with whole-brain radiotherapy (WBRT) to 30 Gy/10 fractions was biologically equivalent with a stereotactic radiosurgery (SRS) boost of 18 Gy/1 fraction with 30 Gy/10 fractions WBRT. Helical tomotherapy (HT) was found to be dosimetrically equivalent to SRS in terms of target coverage and superior to SRS in terms of normal tissue tolerance. A phase I trial has been now completed at our institution with a total of 60 enrolled patients and 48 evaluable patients. The phase II dose has been determined to be the final phase I cohort dose of 60 Gy/10 fractions.

Methods/design: The objective of this clinical trial is to subject the final phase I cohort dose to a phase II assessment of the endpoints of overall survival, intracranial control (ICC) and intralesional control (ILC). We hypothesize HT would be considered unsuitable for further study if the median OS for patients treated with the HT SIB technique is degraded by 2 months, or the intracranial progression-free rates (ICC and ILC) are inferior by 10% or greater compared to the expected results with treatment by whole brain plus SRS as defined by the RTOG randomized trial. A sample size of 93 patients was calculated based on these parameters as well as the statistical assumptions of alpha = 0.025 and beta = 0.1 due to multiple statistical testing. Secondary assessments of toxicity, health-related quality-of-life, cognitive changes, and tumor response are also integrated into this research protocol.

Discussion: To summarize, the purpose of this phase II trial is to assess this non-invasive alternative to SRS in terms of central nervous system (CNS) control when compared to SRS historical controls. A follow-up phase III trial may be required depending on the results of this trial in order to definitively assess non-inferiority/superiority of this approach. Ultimately, the purpose of this line of research is to provide patients with metastatic disease to the brain a shorter course, dose intense, non-invasive radiation treatment with equivalent or improved CNS control/survival and health-related quality-of-life/toxicity profile when compared to SRS radiotherapy.

Trial registration: Clinicaltrials.gov - NCT01543542.

References

    1. Tsao MN, Lloyd NS, Wong RK, Rakovitch E, Chow E, Laperriere N. Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev. 2005;31:256–73. doi: 10.1016/j.ctrv.2005.04.007.
    1. Gaspar L, Scott CB, Rotman M. et al.Recursive partitioning analysis of prognostic factors in three radiation oncology group (RTOG) brain metastasis trials. Int J Rad Oncol Biol Phys. 1997;37:745–751. doi: 10.1016/S0360-3016(96)00619-0.
    1. Sperduto PW, Berkey B, Gaspar LE. et al.A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70:510–514. doi: 10.1016/j.ijrobp.2007.06.074.
    1. Mehta MP, Tsao MN, Whelan TJ. et al.The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 2005;63:37–46. doi: 10.1016/j.ijrobp.2005.05.023.
    1. Lightstone AW, Benedict SH, Bova FJ, Solberg TD, Stern RL. Intracranial stereotactic positioning systems: report of the American Association of Physicists in Medicine Radiation Therapy Committee Task Group no. 68. Med Phys. 2005;32:2380–98. doi: 10.1118/1.1945347.
    1. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Rad Oncol Biol Phys. 1999;45:427–34.
    1. Andrews D, Scott CB, Sperduto PW, Flanders A, Gaspar L, Schell M. et al.Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665. doi: 10.1016/S0140-6736(04)16250-8.
    1. Hall EJ, Brenner DJ. The radiobiology of radiosurgery: rationale for different treatment regimes for AVMs and malignancies. Int J Radiat Oncol Biol Phys. 1993;25:381–5. doi: 10.1016/0360-3016(93)90367-5.
    1. Chase D, Ramsey C, Maha S. The impact of inter- and intra-fraction motion in image guided helical tomotherapy. Int J Rad Oncol Biol Phys. 2004;60:S619.
    1. Mackie TR, Balog J, Ruchala K, Shepard D, Aldridge S, Fitchard E. et al.Tomotherapy. Semin Radiat Oncol. 1999;9:108–17. doi: 10.1016/S1053-4296(99)80058-7.
    1. Beavis AW. Is tomotherapy the future of IMRT? Br J Radiol. 2004;77:285–95. doi: 10.1259/bjr/22666727.
    1. Bauman G, Yartsev S, Rodrigues G. et al.A prospective evaluation of helical tomotherapy. Int J Radiat Oncol Biol Phys. 2007;68:632–641. doi: 10.1016/j.ijrobp.2006.11.052.
    1. Podgorsak EB, Pike GB, Olivier A, Pla M, Souhami L. Radiosurgery with high energy photon beams: a comparison among techniques. Int J Radiat Oncol Biol Phys. 1989;16:857–65. doi: 10.1016/0360-3016(89)90506-3.
    1. Ma L, Xia P, Verhey LJ, Boyer AL. A dosimetric comparison of fan-beam intensity modulated radiotherapy with gamma knife stereotactic radiosurgery for treating intermediate intracranial lesions. Int J Rad Oncol Biol Phys. 1999;45:1325–30. doi: 10.1016/S0360-3016(99)00340-5.
    1. Bolsi A, Fogliata A, Cozzi L. Radiotherapy of small intracranial tumours with different advanced techniques using photon and proton beams: a treatment planning study. Radiother Oncol. 2003;68:1–14. doi: 10.1016/S0167-8140(03)00117-8.
    1. Khoo VS, Oldham M, Adams EJ, Bedford JL, Webb S, Brada M. Comparison of intensity-modulated tomotherapy with stereotactically guided conformal radiotherapy for brain tumors. Int J Radiat Oncol Biol Phys. 1999;45:415–25.
    1. Shaw E, Scott C, Souhami L, Dinapoli R, Bahary J-P, Kline R. et al.Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of radiation therapy oncology group protocol 90-05. Int J Rad Oncol Biol Phys. 1996;34:647–54. doi: 10.1016/0360-3016(95)02106-X.
    1. Bauman G, Yartsev S, Fisher B, Kron T, Laperriere N, Heydarian M, VanDyk J. Simultaneous infield boost with helical tomotherapy for patients with 1 to 3 brain metastases. Am J Clin Oncol. 2007;30:38–44. doi: 10.1097/01.coc.0000245473.41035.c4.
    1. Rodrigues G, Yartsev S, Yaremko B, Perera F, Dar AR, Hammond A. et al.Phase I trial of simultaneous in-field boost with helical tomotherapy for patients with one to three brain metastases. Int J Radiat Oncol Biol Phys. 2011;80:1128–33. doi: 10.1016/j.ijrobp.2010.03.047.
    1. Rodrigues G, Eppinga W, Lagerwaard F, de Haan P, Haasbeek C, Perera F. et al.A pooled analysis of arc-based image-guided simultaneous integrated boost radiation therapy for oligometastatic brain metastases. Radiother Oncol. 2012;102:180–6. doi: 10.1016/j.radonc.2011.05.032.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner